Free tool
FAERS Monitor: Cerebyx
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020450 or its brand name (Cerebyx, Fosphenytoin Sodium). Reports on generic versions are filed under their own applications.
Reports
1,017
Serious
884
87% of reports
Hospitalization
387
Death reported
164
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective127
- off label use70
- hypotension50
- status epilepticus49
- cardiac arrest48
- seizure44
- convulsion41
- pyrexia41
- stevens-johnson syndrome34
- blood pressure decreased30
- toxicity to various agents29
- drug interaction26
- overdose24
- bradycardia23
- medication error23
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 36 |
| 2005 | 33 |
| 2006 | 50 |
| 2007 | 28 |
| 2008 | 28 |
| 2009 | 13 |
| 2010 | 20 |
| 2011 | 22 |
| 2012 | 54 |
| 2013 | 71 |
| 2014 | 72 |
| 2015 | 68 |
| 2016 | 68 |
| 2017 | 89 |
| 2018 | 41 |
| 2019 | 16 |
| 2020 | 39 |
| 2021 | 33 |
| 2022 | 68 |
| 2023 | 59 |
| 2024 | 47 |
| 2025 | 37 |
| 2026 | 25 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,142 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| status epilepticusSignal | 49 | 90.1 | 68.6 | 4,215 |
| stevens-johnson syndromeSignal | 34 | 31.7 | 22.7 | 979 |
| convulsionSignal | 41 | 14.8 | 11.0 | 516 |
| cardiac arrestSignal | 48 | 12.0 | 9.1 | 476 |
| blood pressure decreasedSignal | 30 | 9.3 | 6.6 | 216 |
| bradycardiaSignal | 23 | 9.0 | 6.0 | 155 |
| medication errorSignal | 23 | 8.6 | 5.7 | 146 |
| seizureSignal | 44 | 7.9 | 5.9 | 259 |
| hypotensionSignal | 50 | 5.2 | 3.9 | 165 |
| toxicity to various agentsSignal | 29 | 3.6 | 2.5 | 51 |
| drug interactionSignal | 26 | 3.4 | 2.3 | 42 |
| pyrexiaSignal | 41 | 2.5 | 1.8 | 34 |
| overdoseSignal | 24 | 2.3 | 1.5 | 17 |
| drug ineffective | 127 | 2.0 | 1.7 | 66 |
| off label use | 70 | 1.7 | 1.3 | 18 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.